As of the latest Form 4 filed Jun 9, 2026.
What Iovance Biotherapeutics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Newest filing first — the 28 most recent filings for IOVA.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-09 | 2026-06-05 | Vogt Frederick G Interim CEO & General Counsel | FTax | −6.64K | $4.23 | $28.1K | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | Vogt Frederick G, Interim CEO & General Counsel | MExercise | +15.6K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | FTax | −3.98K | $4.23 | $16.8K | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | GRAF FINCKENSTEIN FRIEDRICH, Chief Medical Officer | MExercise | +7.81K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | Puri Raj K. Chief Regulatory Officer | FTax | −3.84K | $4.23 | $16.3K | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | Puri Raj K., Chief Regulatory Officer | MExercise | +9.77K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | BILINSKY IGOR Chief Operating Officer | FTax | −3.98K | $4.23 | $16.8K | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | BILINSKY IGOR, Chief Operating Officer | MExercise | +7.81K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-03 | 2026-06-01 | Vogt Frederick G Interim CEO & General Counsel | FTax | −17.7K | $3.96 | $70.1K | No | Form 4 ↗ |
| 2026-06-03 | 2026-06-01 | Vogt Frederick G, Interim CEO & General Counsel | MExercise | +41.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-03 | 2026-06-01 | Puri Raj K. Chief Regulatory Officer | FTax | −2.51K | $3.96 | $9.93K | No | Form 4 ↗ |
| 2026-06-03 | 2026-06-01 | Puri Raj K., Chief Regulatory Officer | MExercise | +5.47K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-03 | 2026-06-01 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | FTax | −4.47K | $3.96 | $17.7K | No | Form 4 ↗ |
| 2026-06-03 | 2026-06-01 | GRAF FINCKENSTEIN FRIEDRICH, Chief Medical Officer | MExercise | +8.79K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-03 | 2026-06-01 | BILINSKY IGOR Chief Operating Officer | FTax | −4.47K | $3.96 | $17.7K | No | Form 4 ↗ |
| 2026-06-03 | 2026-06-01 | BILINSKY IGOR, Chief Operating Officer | MExercise | +8.79K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-11 | Kirby Daniel Gordon Chief Commercial Officer | FTax | −2.44K | $3.70 | $9.01K | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-11 | Kirby Daniel Gordon, Chief Commercial Officer | MExercise | +10.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-06 | 2026-03-05 | Vogt Frederick G Interim CEO & General Counsel | FTax | −26.8K | $4.58 | $123K | No | Form 4 ↗ |
| 2026-03-06 | 2026-03-05 | Vogt Frederick G, Interim CEO & General Counsel | MExercise | +62.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-06 | 2026-03-05 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | FTax | −16.5K | $4.58 | $75.7K | No | Form 4 ↗ |
| 2026-03-06 | 2026-03-05 | GRAF FINCKENSTEIN FRIEDRICH, Chief Medical Officer | MExercise | +31.2K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-06 | 2026-03-05 | Puri Raj K. Chief Regulatory Officer | FTax | −18.4K | $4.58 | $84.1K | No | Form 4 ↗ |
| 2026-03-06 | 2026-03-05 | Puri Raj K., Chief Regulatory Officer | MExercise | +39.1K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-06 | 2026-03-05 | BILINSKY IGOR Chief Operating Officer | FTax | −16.6K | $4.58 | $76.2K | No | Form 4 ↗ |
| 2026-03-06 | 2026-03-05 | BILINSKY IGOR, Chief Operating Officer | MExercise | +31.2K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-26 | 2026-02-24 | Kirby Daniel Gordon Chief Commercial Officer | FTax | −34.2K | $3.78 | $129K | No | Form 4 ↗ |
| 2026-02-26 | 2026-02-24 | Kirby Daniel Gordon, Chief Commercial Officer | MExercise | +120K | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also IOVA’s full analysis or the market-wide insider trading feed. The tabs above jump to IOVA’s other SEC data.
Source: SEC Form 4 filings for IOVA, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.